AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: CLINICAL RELEVANCE OF MACROPROLACTIN IN THE ABSENCE OR PRESENCE OF TRUE HYPERPROLACTINEMIA.

OBJECTIVE To review the current literature regarding the prevalence of macroprolactin (macroPRL) in hyperprolactinemic patients and determine recommendations for testing. METHODS An electronic United States National Library of Medicine PubMed search (through October, 2014) was conducted for search term "macroprolactin." Only English-language articles were considered. RESULTS MacroPRL is an under-recognized cause of elevated prolactin (PRL) and is present in approximately 4% to 40% of hyperprolactinemic patients depending on the referral population. Clinical findings which could be due to hyperprolactinemia are the impetus for testing for PRL. Because of this there is significant overlap in the clinical presentation of patients with true hyperprolactinemia and those with macroPRL, differentiation cannot always be made on the basis of symptoms. A lack of recognition of the presence of macroPRL can lead to unnecessary laboratory investigations, imaging, and pharmacologic or surgical treatment. CONCLUSION Until there is a commercially available PRL assay that is not subject to interference by macroPRL, clinicians should consider the possibility of macroPRL, especially if the clinical presentation, imaging findings, and/or response to therapy reveal inconsistencies.

[1]  J. Świętosławski,et al.  Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation. , 2014, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[2]  Thomas P. Smith,et al.  Determination of prolactin: the macroprolactin problem. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[3]  Takashi Adachi,et al.  Possible involvement of matrix metalloproteinase-3 in the pathogenesis of macroprolactinaemia in some patients with rheumatoid arthritis. , 2013, European journal of endocrinology.

[4]  R. Çetinkaya,et al.  Serum prolactin and macroprolactin levels in diabetic nephropathy. , 2012, Clinical nephrology.

[5]  A. Lewiński,et al.  Coexistence of macroprolactinaemia and hyperprolactinaemia in women with oligo-/amenorrhoea is associated with high risk of pituitary adenomas , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  Y. Aydın,et al.  Clinical and radiological findings in macroprolactinemia , 2012, Endocrine.

[7]  A. Lewiński,et al.  Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease , 2012, Thyroid Research.

[8]  H. Boztepe,et al.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed , 2012, Endocrine.

[9]  A. Hoffman,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[10]  A. Shimatsu,et al.  Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long‐term follow‐up , 2010, Clinical endocrinology.

[11]  S. Hunter,et al.  Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. , 2010, The Journal of clinical endocrinology and metabolism.

[12]  C. McCudden,et al.  Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[13]  N. Hattori,et al.  Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers , 2009, Clinical endocrinology.

[14]  T. Mckenna.  Should macroprolactin be measured in all hyperprolactinaemic sera? , 2009, Clinical endocrinology.

[15]  M. Ferraz,et al.  The effect of identifying macroprolactinemia on health-care utilization and costs in patients with elevated serum prolactin levels. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  B. Gellersen,et al.  Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[17]  Thomas P. Smith,et al.  Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients , 2009, Clinical endocrinology.

[18]  B. Harris,et al.  False-positive polyethylene glycol precipitation tests for macroprolactin due to increased serum globulins , 2008, Annals of clinical biochemistry.

[19]  C. Inagaki,et al.  Anti‐prolactin (PRL) autoantibodies suppress PRL bioactivity in patients with macroprolactinaemia , 2008, Clinical endocrinology.

[20]  L. Kavanagh,et al.  Bioactivity of macroprolactin in the Nb2 bioassay may be explained by dissociation yielding bioactive monomeric prolactin , 2007, Clinical endocrinology.

[21]  J. Livesey,et al.  Cross-reactivities of macroprolactin and big-prolactin in three commercial immunoassays for prolactin: a chromatographic analysis. , 2007, Clinical biochemistry.

[22]  V. Goffin,et al.  Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. , 2007, The Journal of rheumatology.

[23]  C. Inagaki,et al.  Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia. , 2007, Endocrinology.

[24]  J. Livesey,et al.  Macroprolactin, big-prolactin and potential effects on the misdiagnosis of hyperprolactinemia using the Beckman Coulter Access Prolactin assay. , 2006, Clinical biochemistry.

[25]  C. Inagaki,et al.  Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. , 2006, The Journal of endocrinology.

[26]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[27]  J. Vieira,et al.  Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  D. Yavuz,et al.  Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy , 2005, Clinical endocrinology.

[29]  J. Gibney,et al.  The impact on clinical practice of routine screening for macroprolactin. , 2005, The Journal of clinical endocrinology and metabolism.

[30]  C. Inagaki,et al.  Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. , 2005, The Journal of clinical endocrinology and metabolism.

[31]  J. Gibney,et al.  Specificity and clinical utility of methods for the detection of macroprolactin. , 2004, Clinical chemistry.

[32]  J. Gibney,et al.  Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. , 2003, Clinical chemistry.

[33]  G. Beckett,et al.  Clinical and radiological features of patients with macroprolactinaemia , 2003, Clinical endocrinology.

[34]  Thomas P. Smith,et al.  Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  J. Vieira,et al.  Screening for macroprolactinaemia and pituitary imaging studies , 2002, Clinical endocrinology.

[36]  D. Hadden,et al.  Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. , 2001, The Journal of clinical endocrinology and metabolism.

[37]  A. Leaños-Miranda,et al.  Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia , 2001, Lupus.

[38]  S. Marcovitz,et al.  Reactivity of macroprolactin in common automated immunoassays. , 2000, Clinical biochemistry.

[39]  Kane,et al.  Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition , 1999, Clinical endocrinology.

[40]  J. Vieira,et al.  Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. , 1998, Clinical chemistry.

[41]  L. Sobrinho,et al.  Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. , 1995, The Journal of clinical endocrinology and metabolism.

[42]  T. Bjøro,et al.  Frequency of hyperprolactinaemia due to large molecular weight prolactin (150-170 kD PRL). , 1995, Scandinavian journal of clinical and laboratory investigation.

[43]  L. Sobrinho,et al.  Characterization of big, big prolactin in patients with hyperprolactinaemia , 1992, Clinical endocrinology.

[44]  E. Russell,et al.  The pituitary "incidentaloma". , 1990, Annals of internal medicine.

[45]  W. Malarkey,et al.  Long-term assessment of patients with macroprolactinemia. , 1988, Fertility and sterility.

[46]  R. Jackson,et al.  Macroprolactinemia presenting like a pituitary tumor. , 1985, The American journal of medicine.

[47]  S. Jeffcoate,et al.  SIZE HETEROGENEITY OF IMMUNOREACTIVE PROLACTIN IN HYPERPROLACTINAEMIC SERUM , 1982, Clinical endocrinology.

[48]  W. Malarkey,et al.  Asymptomatic 'big' hyperprolactinemia in two men with pituitary adenomas. , 1998, European journal of endocrinology.